We are live on ! Find out more
Viking Global Investors

Viking Global Investors Portfolio holdings

AUM $35.7B
1-Year Est. Return 21.3%
This Fund
S&P 500
This Quarter Est. Return
-1.73%
1 Year Est. Return
+21.3%
3 Year Est. Return
+91.13%
5 Year Est. Return
+89.39%
10 Year Est. Return
+464.55%
AUM
$34.7B
AUM Growth
-$1.75B
Cap. Flow
+$171M
Cap. Flow %
0.49%
Top 10 Hldgs %
37.4%
Holding
123
New
26
Increased
25
Reduced
38
Closed
16

Top Buys

Rank Stock Value
1
TWLO icon
Twilio
TWLO
+$891M
2
ROIV icon
Roivant Sciences
ROIV
+$734M
3
BSX icon
Boston Scientific
BSX
+$508M
4
WDAY icon
Workday
WDAY
+$486M
5
AON icon
Aon
AON
+$453M

Sector Composition

Rank Sector Weight
1 Healthcare 37.05%
2 Technology 14.7%
3 Financials 13.93%
4 Industrials 12.17%
5 Consumer Discretionary 11.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
Z icon
76
Zillow
Z
$7.68B
$80.3M 0.23%
+1,258,215
New +$90.7M
IFF icon
77
International Flavors & Fragrances
IFF
$21.7B
$77M 0.22%
+510,985
New +$74.4M
XYZ
78
Block Inc
XYZ
$47.5B
$73.5M 0.21%
+454,947
New +$98.6M
XPEV icon
79
XPeng
XPEV
$11.4B
$73.3M 0.21%
+1,456,496
New +$65.7M
AMED
80
DELISTED
Amedisys
AMED
$63.3M 0.18%
+391,131
New +$62.9M
KKR icon
81
KKR & Co
KKR
$99.6B
$60.1M 0.17%
+806,081
New +$59.5M
BEKE icon
82
KE Holdings
BEKE
$18.7B
$58.8M 0.17%
+2,920,256
New +$59.8M
PHM icon
83
Pultegroup
PHM
$25.2B
$52.2M 0.15%
+913,668
New +$46.8M
TRML
84
DELISTED
Tourmaline Bio
TRML
$50.3M 0.14%
328,962
BHVN
85
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$48.1M 0.14%
+348,783
New +$44.4M
OLPX
86
DELISTED
Olaplex Holdings
OLPX
$47M 0.14%
1,613,189
-1,409,183
-47% -$37.4M
EWTX icon
87
Edgewise Therapeutics
EWTX
$4.81B
$41.7M 0.12%
2,727,249
PMVP icon
88
PMV Pharmaceuticals
PMVP
$69.3M
$41.4M 0.12%
1,790,284
ICVX
89
DELISTED
Icosavax, Inc. Common Stock
ICVX
$41.1M 0.12%
1,796,800
-55,989
-3% -$1.45M
RLYB icon
90
Rallybio
RLYB
$87M
$40M 0.12%
524,347
APO icon
91
Apollo Global Management
APO
$82.8B
$39M 0.11%
+538,212
New +$38.8M
PHVS icon
92
Pharvaris
PHVS
$2.41B
$38.8M 0.11%
2,455,536
+64,019
+3% +$999K
OHPAU
93
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$36.1M 0.1%
3,669,272
-2,516
-0.1% -$24.9K
VTEX icon
94
VTEX
VTEX
$670M
$32.4M 0.09%
3,023,280
-17,616
-0.6% -$276K
KNTE
95
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$32.3M 0.09%
1,820,462
NUVL
96
DELISTED
Nuvalent
NUVL
$31.4M 0.09%
1,647,671
ABMD
97
DELISTED
Abiomed Inc
ABMD
$29.7M 0.09%
+82,572
New +$27.9M
CLDX icon
98
Celldex Therapeutics
CLDX
$3.48B
$29.3M 0.08%
757,881
-4,415
-0.6% -$192K
DAWN
99
DELISTED
Day One Biopharmaceuticals
DAWN
$19.5M 0.06%
1,157,424
-53,972
-4% -$1.11M
TDCX
100
DELISTED
TDCX Inc. American Depositary Shares, each representing one Class A ordinary share
TDCX
$19.4M 0.06%
+1,014,497
New +$22.3M

Similar funds

Viking Global Investors's Q4 2021 Portfolio in Review

As of Q4 2021, Viking Global Investors held 123 positions worth $34.7B, down 4.8% from $36.5B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Viking Global Investors's Q4 2021 filing shows 26 new, 25 increased, 38 reduced and 16 closed positions. Its largest new stake was Twilio: 2,980,398 shares worth $785M. The largest sale was Fidelity National Information Services, an estimated $873M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 38% a quarter earlier, followed by Technology and Financials.

  • Viking Global Investors's largest Q4 2021 buy was Twilio: 2,980,398 shares worth $785M.
  • Viking Global Investors added most to Boston Scientific in Q4 2021, an estimated $508M increase.
  • Viking Global Investors's biggest Q4 2021 reduction was McDonald's, cutting an estimated $513M.
  • Viking Global Investors fully exited Fidelity National Information Services in Q4 2021, selling an estimated $873M.
  • Viking Global Investors's ten largest holdings make up 37% of its $34.7B portfolio in Q4 2021.
  • Viking Global Investors opened 26 new positions and closed 16 in Q4 2021.
  • Viking Global Investors's portfolio value fell 4.8% quarter-over-quarter to $34.7B.

Based on Viking Global Investors's 13F filing for Q4 2021, filed 14 Feb 2022.